Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPF induction chemotherapy and chemoradiation in advanced head and neck squamous cell carcinoma with FAZA PET hypoxia assessment
ACTRN12609000642280Phase 3Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jan 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of docetaxel, cisplatin and fluorouracil in head and neck squamous cell carcinoma (HNSCC), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Change in intratumoral hypoxia after TPF. Started Jan 2010; status: recruiting.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ACTRN12609000642280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000642280.